Related Experiment Video
Updated: Apr 14, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.7K
Biologic Efficacy by BMI in Moderate-To-Severe Psoriasis: A Real-World Cohort Study.
Xin Shen1, Fan Wang1, Rui Wang1
1Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Experimental Dermatology
|April 13, 2026
Summary
Obesity impacts biologic therapy effectiveness in psoriasis patients. Interleukin-17 (IL-17) and Interleukin-23 (IL-23) inhibitors are more effective for non-overweight individuals, while IL-23 inhibitors offer sustained response in overweight/obese patients.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Obesity is known to reduce the effectiveness of biologic therapies for psoriasis.
- Limited comparative data exists on how obesity affects different biologic drug classes in Chinese patients.
Purpose of the Study:
- To investigate the impact of Body Mass Index (BMI) on the effectiveness and drug survival of IL-17, IL-23, and TNF-α inhibitors in Chinese adults with moderate-to-severe psoriasis.
- To compare the real-world effectiveness of different biologic drug classes based on patient BMI.
Main Methods:
- A real-world cohort of 891 adult psoriasis patients initiating biologics (2020-2025) was analyzed.
- Patients were stratified by baseline BMI (<24 kg/m² vs. ≥24 kg/m²).
- Psoriasis Area and Severity Index 90 (PASI90) achievement and drug survival were compared across IL-17, IL-23, and TNF-α inhibitors.
Main Results:
- Among IL-17 inhibitor users, non-overweight patients showed significantly higher PASI90 rates at 4, 6, and 12 months compared to overweight/obese patients.
- No significant BMI-related differences in response were observed for TNF-α or IL-23 inhibitors.
- In non-overweight patients, IL-17 and IL-23 agents outperformed TNF-α inhibitors at 6 months with fewer treatment switches.
- In overweight/obese patients, IL-23 inhibitors demonstrated the highest PASI90 rates and longest drug survival compared to IL-17 and TNF-α inhibitors.
Conclusions:
- Patient BMI influences biologic therapy effectiveness in a drug-specific manner for Chinese psoriasis patients.
- IL-17 and IL-23 inhibitors show favorable outcomes in non-overweight individuals.
- IL-23 inhibitors may provide a more sustained response for overweight or obese psoriasis patients.
Related Concept Videos
01:13Bioequivalence studies: Biowaivers
414
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
414
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
802
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
802
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
223
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
223
01:27Bioavailability Study Design: Absolute Versus Relative Bioavailability
601
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
601
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
352
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
352
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
565
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
565